1. Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence

3. Program Goals

4. Insulin Deficiency and Glucagon Hypersecretion in T2D

5. Postprandial Glucagon Is Excessive and Not Corrected by Exogenous Insulin

6. Incretin Hormome Physiology

7. Signal Transduction and GLP-1

10. Summary of Main GLP-1 Effects

12. 2012 ADA/EASD Position Statement

13. Impact of Exenatide Twice-Daily Therapy Over 3 Years: Effect on HbA1c and Body Weight

16. Considerations in Choosing a GLP-1 Receptor Agonist

17. EXN Once Weekly vs Sitagliptin and Pioglitazone: HbA1c Reduction

19. Nausea With GLP-1 Receptor Agonists Tends to Decrease With Time

20. Strategies to Minimize the Occurrence of Nausea

21. Minor Hypoglycemia* With GLP-1 Receptor Agonists

22. Liraglutide/Exenatide: Black Box Warning Risk of Thyroid C-Cell Tumors

23. Incretin-based Therapies: Concern About Acute Pancreatitis

24. Sitagliptin and Exenatide Associated With Increased Risk for Hospitalization for Acute Pancreatitis

25. Incretin-based Therapies: Renal Impairment

26. Incretin-based Therapies Associated With Increased Alpha-Cell Hyperplasia

27. Exenatide Twice Daily Added to Insulin Glargine

28. Closing Comments

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)

32. References

33. References (cont)

34. References (cont)

35. References (cont)

36. References (cont)

37. References (cont)